Cancer (bio)networking

Perhaps the most significant challenge in finding prognostic markers for human diseases is the fact that most diseases don’t involve individual genes but rather complex networks
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LA JOLLA, Calif.—Perhaps the most significant challenge in finding prognostic markers for human diseases is the fact that most diseases don't involve individual genes but rather complex networks of interacting proteins and other biomolecules. With this in mind, researchers at UCSD and the Korea Advanced Institute of Science and Technology recently correlated breast cancer gene expression patterns with protein interaction databases to identify metabolic networks of cancer metastasis.
Continue reading below...
An illustration showing red cancer cells surrounded by white immune cells interacting on a dark textured background.
ExplainersWhy does immunotherapy work better for some cancers than others?
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.
Read More
As they describe in Molecular Systems Biology, the researchers took microarray data from two cohorts of breast cancer patients, dividing the expression profiles into "metastatic" and "non-metastatic" groups. They then overlaid this data onto a pooled data set of almost 60,000 interactions of more than 11,000 proteins derived from yeast two-hybrid experiments, predicted from orthology, or curated in the literature. In total, they identify almost 400 subnetworks, which they have made available online as the Cell Circuits database.
The researchers found there was significantly more overlap between the two data sets at the subnetworks level than the single genes level and were relatively predictive of metastatic prognosis both within and across breast cancer cohorts. Furthermore, using the subnetwork system, the researchers could identify well established prognostic markers that are not identified in conventional gene expression screens, including HER2/neu, myc, and cyclin D1.
Concluded the researchers: "At present, the success of network-based pathways identification and classification support the notion that cancer is indeed a 'disease of pathways' and that the keys for understanding at least some of these pathways are encoded in the protein network."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue